MAIN ARTICLE
A family’s hopes meet an unproven intervention
According to the Shanghai investigative task force's findings published by Xinhua, the family approached scientist Qiu Zilong in July 2023 seeking a treatment tailored to their daughter. Snijders Blok-Campeau syndrome is associated with alterations in the CHD3 gene and can affect language, learning and development. For parents facing a rare condition without an established cure, experimental science can appear to offer a way forward. Yet the urgency of a family’s search cannot substitute for evidence that an intervention is reasonably safe and potentially beneficial.
The team undertook preclinical work, involving companies in Guangzhou and Sichuan to manufacture a viral vector and conduct safety tests in large animals. Xinhua Hospital's ethics committee approved the clinical study in January 2025. The girl received an injection in March and died on March 31, 2025. The hospital attributed her death to thrombotic microangiopathy associated with gene therapy. That sequence illustrates the distance between a promising molecular concept and a sufficiently tested intervention in a child's body.
Investigators find gaps in safety review and disclosure
The inquiry found that troubling preclinical safety findings were not promptly shared with relevant parties. A paper published in Nature in February 2026 omitted adverse research findings and did not properly disclose conflicts of interest.
















